Archive
549 articles, sorted by publication time.
As SK Biopharmaceuticals accelerates its AI drug development strategy, NVIDIA is said to be turning its attention to South Korean biobanks; the signal is a reminder to the industry that the truly scarce resource may not only be computing power, but human data that can be used responsibly and connected back to real disease settings.
A candidate vaccine from Cambridge and DIOSynVax has crossed an early human safety threshold, moving the idea of “pre-positioning defenses against the next coronavirus” from an algorithmic concept to a clinical question: whether it can translate into real protection in larger trials.
A recent commentary questions the evidence balance behind drug approval through the lens of “two wins and eleven losses”; the real issue is not just the numbers, but how regulators judge the weight of efficacy signals, failed trials, and patient needs.
If zilganersen receives FDA clearance, it will face more than the final mile of scientific validation; for an ultra-rare neurological disease, how to deliver the drug to a small number of patients scattered across regions will also determine whether the therapy can truly take hold.
Otsuka’s centanafadine met the goal in a Phase 3b trial of adults with ADHD and comorbid anxiety, adding data closer to everyday clinical practice to an application nearing its FDA decision date; however, these are still topline results, and the magnitude of efficacy and safety details will need to be assessed after full publication.
As cases accumulate rapidly and no specific drugs or vaccines have yet been approved, WHO is moving Mapp’s MBP134 and Gilead’s remdesivir into clinical testing; this is not a declaration of victory, but the most urgent and difficult generation of evidence during an outbreak.
This approval brings a CDK4/6 inhibitor into the more complex setting of double-positive breast cancer; its significance is not the addition of another drug name, but a shift in treatment rhythm from suppressing tumors to extending the period of stability.
AI is rewriting the starting line for molecular design, but the path from a viable candidate to a usable drug remains a long one, jointly guarded by experiments, humans, and regulators.
DelveInsight’s latest market research lays out the multiple sclerosis R&D landscape anew: major pharmaceutical companies and biotech firms are still looking for treatment paths that are more precise, more convenient, and better able to address progressive disease, but the information itself remains an industry review rather than a breakthrough in new therapies.
The AI-designed vaccine from Cambridge and DIOSynVax has completed its first human trial; the real new signal is not in the word “universal,” but in how Phase 2 will show whether it can produce meaningful clues of protection against an entire family of viruses.
Fibrolamellar hepatocellular carcinoma has long made it difficult for immune checkpoint drugs to take effect; new research points to “T-cell exclusion” in the tumor microenvironment and, in patient tumor slices, finds that the FDA-approved drug AMD3100 may be able to remove this barrier.
This is not news sufficient to declare a drug breakthrough, but a signal: AI drug development is shifting from demonstrating platform capabilities to pharmaceutical companies outsourcing and validating early biological risk in stages.